Multiparametric Imaging-based Intraoperative Navigation for Guidance of Surgical Resection and Postoperative Radiotherapy in Patients With Head-and-neck Tumors
NCT05671458 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2026-01-12
Summary
The overarching goal of the NAVIGATORR trial is the improvement of local tumor control in head-and-neck cancer (HNC) by increasing the precision of surgical resection and individualization of radiotherapy. Squamous cell carcinomas (SCC) together with salivary gland carcinomas (adenoid cysytic Carcinoma (ACC), mucoepidermoid Carcinoma (MEC), adenocarcinoma (AC)) represent the most common entities in German head and neck oncology. In localized tumors, primary tumor resection with possible adjuvant (chemo)radiotherapy is still the treatment of choice. Advances in targeted therapy and immunotherapy have greatly expanded the repertoire of medical oncology in recent years. In particular, prognosis of patients with end-stage non-small cell lung cancer (NSCLC) has been improved and even patients with advanced head and neck disease can be offered new second line regimes. Importantly, all of these advances are based on personalized and targeted therapies. Unfortunately, surgical oncology in the head-and-neck region has not yet shown such developments towards individualized treatment, so that the rates of safe oncological resections (clear resection margins) haven been stagnating. Despite advances in reconstructive surgery that allow the resection of head-and-neck tumors that would not have been operable 10 - 15 years ago, the basic principles of the resection margin and especially margin evaluation have remained unchanged. The technique of navigation-based tumor resection and the annotation of biopsies by titanium clip-markings or special annotation have been described, but only in small case series and without proving the benefit of the method concerning clinically relevant parameters.
Therefore, the NAVIGATORR trial will enroll 60 patients with HNC of the midface that will undergo navigation-based surgery. Importantly, interdisciplinary data exchange of the intraoperative navigation data between surgeons, pathologists and radiation oncologists will be established. Clear surgical margins (distance between tumor cells and resection border \> 5 mm) have been defined as primary endpoint. Secondary endpoints such as dosimetric assessment of individualized radiotherapy plans, local tumor control or overall survival should then be compared to data from the literature to further assess this multidisciplinary approach.
Conditions
- Head and Neck Tumors
Interventions
- OTHER
-
intraoperative navigation and creation of tumor resection maps
TRM are based on intraoperative navigation data and yield anatomically accurate marks of the tumor resection margin and potential residual tumor areas on clinical imaging. These marks will be annotated with histopathological information. Subsequently, the resulting 3-dimensional TRM will be imported into the radiotherapy planning system as part of a multidisciplinary workflow.
Sponsors & Collaborators
-
Juergen Debus
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-01-01
- Primary Completion
- 2027-01-01
- Completion
- 2027-01-01
Countries
- Germany
Study Locations
More Related Trials
-
A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma
NCT06894459 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck
NCT00570674 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
ctDNA and MRI Parameters in Head and Neck Cancer
NCT06215612 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer
NCT00140556 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
NCT00023959 ·Status: COMPLETED ·Phase: PHASE1
-
Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients
NCT05504642 ·Status: WITHDRAWN ·Phase: PHASE2
-
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence
NCT01142414 ·Status: WITHDRAWN ·Phase: PHASE3
-
Proximal Molecular Effects of Concurrent Chemoradiotherapy on Head and Neck Squamous Cell Carcinoma
NCT00620139 ·Status: COMPLETED
-
External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
NCT06543576 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Carbon Ion Re-Radiotherapy in Patients With Recurrent or Progressive Locally Advanced Head-and-Neck Cancer
NCT04185974 ·Status: RECRUITING ·Phase: NA
-
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
NCT00956007 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
NCT03765918 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Optimization of Cervical Nodal CTV for Early and Medium Stage NPC
NCT05145660 ·Status: RECRUITING ·Phase: PHASE3
-
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
NCT05063552 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Salvage Brachytherapy and Hyperthermia for Recurrent H&N-tumours
NCT03238378 ·Status: RECRUITING ·Phase: NA
-
Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT01592721 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
NCT00281840 ·Status: COMPLETED ·Phase: PHASE2
-
Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma
NCT06957938 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
NCT01312350 ·Status: COMPLETED ·Phase: PHASE2
-
Proton Therapy for Locally Advanced Cervical Cancer
NCT06462378 ·Status: RECRUITING ·Phase: PHASE2
-
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
NCT06288373 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer
NCT04834349 ·Status: WITHDRAWN ·Phase: PHASE2
-
Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin
NCT04533750 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Near-Infrared Image Guided Surgical Resection With Indocyanine Green in Treating Patients With Head and Neck Cancer
NCT03745690 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
NCT05172245 ·Status: RECRUITING ·Phase: PHASE1